For personal use only

26 October 2026

ASX Announcement

September 2026 Quarterly Activities Report

- **Government and regulatory approvals secured for the compassionate use of Galidesivir in patients infected in the Bundibugyo Ebola outbreak in Uganda**
- **Real-world use of Galidesivir in Africa establishes an opportunity to generate prospective human clinical data**
- **Statement of Work executed with Texas Biomedical Research Institute (Texas Biomed) for complementary 12-animal Galidesivir dose optimisation study**
- **Texas BioMed study strengthens Island's FDA Animal Rule development pathway, prior to commencement of pivotal study and FDA submission**
- **Combined USAMRIID and Texas Biomed programs designed to generate data from 32 non-human primates (NHPs), supporting dose selection and the design of a planned pivotal Marburg efficacy study**
- **Signed Letter of Authorisation secured providing regulatory access to detailed Marburg-Angola natural history data, directly addressing a requirement identified by the US FDA**
- **Second GMP manufacturing campaign commissioned to expand Galidesivir inventory**
- **~700–800 treatment courses targeted for availability this quarter with drug expected to be shipped to Africa prior to end of CY26**
- **Singapore patent granted covering the use of ISLA-101 for the treatment of flavivirus infections, including Dengue, and Chikungunya virus infection**
- **Subsequent to quarter end, GMP manufacture of Galidesivir API commenced, with first 5kg batch targeted for completion by the end of this month**
- **USAMRIID study preparations advanced following quarter end, with 22 NHPs successfully completing screening and preparation requirements ahead of planned dosing in Q4 CY26**

MELBOURNE Australia, 26 October 2026: Australian antiviral drug development and biodefence company, Island Pharmaceuticals Ltd (**ASX: ILA**; **Island** or **the Company**) is pleased to provide the following summary of activities undertaken during the three-month period ended 30 September 2026 (**quarter**).

During the period, Island made significant progress across its Galidesivir development program, advancing multiple regulatory, manufacturing and operational initiatives to support its development as a broad-spectrum medical countermeasure for high-consequence viral diseases.

The period was highlighted by several key achievements, including the securing of government and regulatory approvals for the compassionate use of Galidesivir during the ongoing Bundibugyo Ebola outbreak. Island also executed a complementary dose optimisation study with Texas Biomedical Research Institute (Texas Biomed), a key step which strengthens its regulatory application process for Galidesivir under the Animal Rule development pathway. Also during the period, Island received of a Letter of Authorisation providing access to important Marburg natural history data and expanded the scope of its GMP-compliant manufacturing program for Galidesivir.

Collectively, these initiatives have strengthened Island's dual development strategy, combining the opportunity to generate prospective human clinical data in Ebola patients with an established regulatory pathway for Marburg virus disease under the US Food and Drug Administration's (FDA) Animal Rule.

Subsequent to the end of the quarter, Island commenced physical GMP manufacture of Galidesivir API and confirmed completion of non-human primate (NHP screening and preparation requirements ahead of its planned United States Army Medical Research Institute of Infectious Diseases (USAMRIID) dose optimisation study, which is expected to commence dosing this quarter.

Management commentary:

Chief Executive Officer and Managing Director, Dr David Foster, said: *"The September quarter represents another important period of progress as we continued to execute on our strategy to advance Galidesivir as a broad-spectrum medical countermeasure for some of the world's most significant viral threats.*

"Importantly, we have continued to build on the substantial body of existing Galidesivir data through two complementary development pathways. Our FDA-directed Marburg program is progressing towards the next phase of animal efficacy studies, while the approvals secured in Uganda have established a rare opportunity to generate prospective human clinical data during an active Ebola outbreak.

"The execution of our agreement with Texas Biomed and receipt of the Marburg natural history Letter of Authorisation represent important regulatory milestones. Together with our ongoing collaboration with USAMRIID, these initiatives further strengthen the evidence package required to support our planned pivotal Animal Rule study.

"We have also taken important steps to expand our manufacturing capabilities and establish a meaningful inventory of GMP-grade Galidesivir. This is a critical component of our strategy, providing the flexibility to support planned development activities while positioning Island to respond to emerging outbreak and biodefence opportunities.

"Subsequent to quarter end, we were particularly pleased to commence physical GMP manufacturing and confirm the successful completion of screening and preparation requirements for the animals involved in our upcoming USAMRIID study. These developments demonstrate the continued transition of our program from regulatory planning into execution.

"Looking ahead, our immediate priorities are to complete the current manufacturing campaigns, advance the USAMRIID and Texas Biomed studies and progress preparations for the deployment of Galidesivir under the approved Uganda emergency-use program.

"With multiple development activities now progressing in parallel, we believe Island is well positioned to continue building the clinical, regulatory and manufacturing foundations required to support Galidesivir's potential approval and future commercialisation."

For personal use only

For personal use only

Operational overview:

Government approvals secured for Galidesivir treatment during Bundibugyo Ebola outbreak:

Island secured all required government, regulatory and ethics approvals to enable the compassionate use of Galidesivir in patients infected during the ongoing Bundibugyo Ebola outbreak in Uganda.

The approvals allow Galidesivir to be administered under the World Health Organization's (WHO) recognised Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework, which enables access to investigational therapies during public health emergencies where approved treatment options are unavailable.

The program is being undertaken in collaboration with the Uganda Ministry of Health, the ACCEPT-Africa Consortium and the Infectious Diseases Institute at Makerere University, following completion of the relevant regulatory and ethics review processes.

Importantly, the initiative provides Island with an opportunity to generate prospective human clinical, safety and virological data from patients treated with Galidesivir during an active Ebola outbreak.

This represents an important addition to the Company's development strategy, potentially providing human evidence in the intended disease setting while complementing its existing FDA Animal Rule pathway for Marburg virus disease.

The program is sponsored and funded by the participating government and supporting institutions. This provides a capital-efficient opportunity to advance the Company's clinical development program while supporting efforts to address an urgent public health need.

Galidesivir has an established body of preclinical and clinical data, including previous NHP studies demonstrating 100% survival in Galidesivir-treated animals infected with Ebola Zaire virus, compared with no survival in placebo-treated controls.

The ongoing Bundibugyo Ebola outbreak has further highlighted the need for broad-spectrum antiviral therapies capable of addressing multiple filovirus threats. Unlike Ebola Zaire, there are currently no approved specific therapeutic treatments for Bundibugyo Ebola virus disease.

Island continues to progress the manufacturing and operational activities to support the proposed deployment of Galidesivir in Uganda, with the objective of generating prospective human data alongside its ongoing Marburg development program.

Texas Biomed agreement expands FDA-directed dose optimisation program:

During the quarter, Island executed a Statement of Work (SOW) with Texas Biomed, establishing a complementary Galidesivir dose optimisation study as part of the Company's development program for Marburg virus disease.

The agreement expands Island's FDA-directed dose optimisation strategy through a second study at a specialised Biosafety Level 4 (BSL-4) facility in the US complementing the existing program being undertaken with the USAMRIID.

Under the agreement, Texas Biomed will evaluate Galidesivir in 12 NHPs infected with the Angola strain of Marburg virus, the FDA-preferred challenge strain for the Company's Animal Rule development program.

The study has been designed to assess Galidesivir when treatment is initiated following the onset of clinical signs of infection, typically between three- and five-days following exposure.

This complements the planned 20-NHP USAMRIID study, which will evaluate treatment initiated at earlier post-exposure timepoints of 24 and 48 hours.

Together, the two studies are designed to generate complementary efficacy, pharmacokinetic, dose-response and treatment-timing data across multiple therapeutic windows.

The combined 32-NHP program is expected to provide important evidence to inform dose selection, optimise treatment parameters and support the design of Island's planned pivotal efficacy study under the FDA Animal Rule pathway.

Importantly, Island also secured access to an additional cohort of animals through Texas Biomed should further optimisation work be required, providing operational flexibility as the program advances.

Study preparation activities at Texas Biomed are scheduled to commence this quarter, with the infection and treatment phase targeted for early CY27.

The agreement further strengthens Island's relationships with leading US biodefence and infectious disease institutions while advancing the Company's broader strategy to develop Galidesivir as a potential medical countermeasure for Marburg virus disease.

Marburg natural history data secured to support FDA Animal Rule pathway:

Island received a signed Letter of Authorisation (LOA) providing the Company with the regulatory right to cross-reference a detailed Marburg-Angola NHP natural history study in future submissions to the FDA.

The LOA represents an important regulatory milestone and directly addresses an information requirement identified by the FDA during previous engagement regarding Galidesivir's proposed Animal Rule development pathway.

The FDA Animal Rule provides a potential approval pathway for medical countermeasures targeting diseases where conventional human efficacy studies are unethical or infeasible.

Under this framework, appropriately characterised animal disease models are required to demonstrate efficacy and support a reasonable prediction of clinical benefit in humans.

Natural history studies provide an important foundation for these models by characterising the progression of disease in the absence of treatment, establishing the baseline against which the efficacy of an investigational therapy can be assessed.

During previous regulatory discussions, the FDA indicated that the published information available on Island's proposed Marburg NHP model was insufficiently detailed to fully assess its suitability for an Animal Rule submission.

Following more than six months of negotiations, Island secured the necessary

For personal use only

regulatory access to the complete natural history study report, enabling the Company to cross-reference the data in future FDA submissions.

Importantly, the agreement allows Island to leverage an existing body of Marburg-specific research rather than independently undertaking an equivalent natural history study, avoiding potentially significant additional development costs and time.

The dataset provides an important regulatory foundation for the Company's upcoming dose optimisation studies at USAMRIID and Texas Biomed and strengthens the overall evidence package supporting its planned pivotal Animal Rule efficacy program.

Expanded GMP manufacturing to support outbreak and biodefence opportunities:

During the quarter, Island commissioned a second manufacturing campaign of GMP-grade Galidesivir with PI Health Sciences (PIHS), expanding the Company's planned drug inventory to support active outbreak response, clinical development and broader biodefence opportunities.

The additional campaign builds on the Company's existing manufacturing agreement with PIHS and is intended to materially increase the available supply of Galidesivir.

Following completion of the manufacturing program, Island expects to have approximately 700–800 treatment courses of GMP-grade Galidesivir available this quarter.

The decision to expand manufacturing reflects the increasing breadth of opportunities across the Galidesivir program, including the approved Uganda emergency-use initiative, planned Marburg efficacy studies and potential future government procurement and biodefence stockpiling opportunities.

Establishing a meaningful inventory of GMP-grade material is an important component of Island's broader development strategy, providing the flexibility to respond to emerging infectious disease threats without requiring a new manufacturing campaign for each potential opportunity.

The expanded program also supports the establishment of the manufacturing, analytical and quality systems required for Galidesivir's ongoing development and potential future regulatory submissions.

The Company continues to progress manufacturing activities alongside its clinical and regulatory initiatives, with the objective of establishing sufficient supply to support its near-term development priorities and longer-term commercial opportunities.

ISLA-101 intellectual property portfolio strengthened:

Island received confirmation that the Intellectual Property Office of Singapore had granted a patent protecting the use of ISLA-101 for the treatment of flavivirus infections, including Dengue, and Chikungunya virus infection.

The patent, titled '*Method of Viral Inhibition*' (Singapore Patent No. 10202011533P), includes claims covering the use of ISLA-101 as a standalone antiviral therapy and provides protection until 16 April 2034.

The patent is owned by Monash University and forms part of Island's exclusively licensed intellectual property portfolio supporting the development and commercialisation of ISLA-101.
The grant strengthens the Company's intellectual property position in an important

For personal use only

Asia-Pacific market where Dengue and other mosquito-borne viral diseases continue to represent significant public health challenges.

It also broadens the scope of protection beyond Dengue to include Chikungunya virus infection, supporting potential future development and commercialisation opportunities across multiple viral indications.

Island continues to maintain and develop its ISLA-101 IP portfolio as part of its broader strategy to maximise the long-term value of the program.

Subsequent events:

GMP manufacture of Galidesivir API commences:

Subsequent to quarter end, Island confirmed that physical GMP manufacture of Galidesivir API commenced on 1 October 2026 at PI Health Sciences.

The multi-step manufacturing process is now underway, with the first 5kg batch of GMP-grade Galidesivir API targeted for completion by the end of October 2026.

This first batch has been earmarked to support Island's approved emergency-use program in Uganda during the ongoing Bundibugyo Ebola outbreak.

Following completion of API manufacturing, Island will undertake the necessary finishing, vialing and packaging activities ahead of the planned shipment of Galidesivir for investigational therapeutic use under the WHO MEURI framework.

A second 5kg GMP API batch is targeted for completion by the end of November 2026 and is intended to support the Company's broader Ebola strategy and planned Marburg development activities under the FDA Animal Rule pathway.

The commencement of physical manufacturing represents an important execution milestone, supporting Island's objective of establishing GMP supply for prospective human Ebola data generation, planned Marburg studies and potential future biodefence opportunities.

USAMRIID Marburg study advances towards dosing:

Subsequent to the end of the quarter, it was confirmed that 22 NHPs had successfully completed screening and preparation requirements ahead of its planned 20-animal Galidesivir dose optimisation study at USAMRIID.

All animals successfully completed health and suitability assessments and specialised training requirements, including acclimatisation to the jackets and tethering systems required for study procedures and pharmacokinetic sampling.

The completion of these activities confirms that sufficient qualified animals are available for the study, with 20 NHPs required for participation and two additional animals available as reserves.

The study will evaluate Galidesivir against the Angola strain of Marburg virus, with treatment initiated at either 24- or 48-hours following infection.

Varying dose regimens will be administered intravenously over a 14-day treatment period, with the primary endpoint assessing survival at 28 days post-exposure. Additional assessments will include viral load, clinical signs, pharmacokinetics and other disease-related parameters.

For personal use only

Dosing is anticipated to commence during this quarter, with study observations expected to conclude approximately 30 days following commencement and topline results to follow completion and analysis.

The study represents an important component of Island's FDA-aligned development strategy, generating data intended to inform dose selection and the design of the Company's planned pivotal confirmatory efficacy study.

Together with the complementary Texas Biomed program, the study will progressively expand Galidesivir's efficacy dataset and further strengthen the Company's regulatory package supporting its potential development as a treatment for Marburg virus disease.

Ongoing investor engagement:

Island continued to actively engage with shareholders, institutional investors and the broader investment community during the quarter through investor presentations, webinars and targeted market engagement activities.

Management presented at the TechKnow Invest Roadshow in Melbourne and Sydney, as well as the Bioshares 2026 conference, providing updates on the Company's Galidesivir development program, FDA Animal Rule regulatory pathway and expanding opportunities across infectious diseases and biodefence.

The Company also hosted investor webinars following key regulatory and operational developments, including approvals for the compassionate use of Galidesivir during the Bundibugyo Ebola outbreak and progress across its FDA-directed Marburg development program. These initiatives provided shareholders with further insight into Island's clinical development strategy, upcoming milestones and potential commercial opportunities.

Outlook and upcoming milestones:

Island enters the December quarter with multiple development activities progressing across its Galidesivir program. The Company's immediate priorities include:

- **USAMRIID dose optimisation study:** Commencement of the planned 20-NHP study evaluating Galidesivir against Marburg-Angola virus, with topline results to follow study completion and analysis
- **Texas Biomed study:** Progression of preparation activities ahead of the planned 12-NHP study, with the infection and treatment phase targeted for early CY27.
- **Galidesivir manufacturing:** Completion of the first and second 5kg GMP API manufacturing batches, targeted for October and November CY26 respectively, followed by required finishing and quality activities
- **Uganda emergency-use program:** Continued preparation for the deployment of Galidesivir under the approved MEURI framework, providing an opportunity to generate prospective human clinical, safety and virological data
- **FDA Animal Rule development:** Continued progression of the regulatory evidence package, incorporating natural history data and results from planned dose optimisation studies to inform the design of the pivotal efficacy program
- **Government and biodefence engagement:** Continued engagement with relevant government agencies, infectious disease institutions and potential strategic partners regarding outbreak preparedness, medical countermeasure development and future procurement opportunities.

For personal use only

Collectively, these initiatives are expected to advance Island's dual development strategy while strengthening the clinical, regulatory and manufacturing foundations supporting the potential commercialisation of Galidesivir.

Financial summary:

The Company held cash and cash equivalents of $7.83m at 30 September 2026 (30 June 2026: A$12.87m). The Company anticipates additional cash inflows of up $1.36m during the December 2026 quarter from the exercise of options in the money (19,428,696 options expiring 4 December 2026, with exercise price of $0.07 per option). Net cash used in operating activities during the quarter totalled $4.9m, reflecting expenditure associated with the ongoing development of Galidesivir and ISLA-101. This included expenses associated with the pending USAMRIID dose escalation study, securing non-human primates associated with the Texas Biomed study BSL-4 facility costs, regulatory efforts in connection with clinical efforts in Africa and GMP manufacturing.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C totalled $227,000, comprising salary and FY26STI remuneration for the CEO and Managing Director, Non-Executive Director fees and their consulting fees, where applicable.

Further details of the Company's cash flows, financing activities and available funding are provided in the accompanying Appendix 4C.

- Ends -

Approved for release to the ASX by the Board.

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

ISLAND PHARMACEUTICALS LIMITED

ABN	**Quarter ended ("current quarter")**
48 641 183 842	30 September 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for	-	-
	(a) research and development	(4,298)	(4,298)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(154)	(154)
	(f) administration and corporate costs	(541)	(541)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	67	67
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)		-
1.9	**Net cash from / (used in) operating activities**	**(4,926)**	**(4,926)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-

For personal use only

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	22	22
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**22**	**22**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	12,871	12,871
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,926)	(4,926)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

For personal use only

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	22	22
4.5	Effect of movement in exchange rates on cash held	(139)	(139)
4.6	**Cash and cash equivalents at end of period**	**7,828**	**7,828**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	4,889	6,855
5.2	Call deposits	2,939	6,016
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**7,828**	**12,871**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	227
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

The amount at 6.1 includes salary and FY26 STI bonus for the CEO/Managing Director and Director fees (including superannuation) for the Non-Executive Chair and Non-Executive directors and their consulting fees, where applicable.

For personal use only

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	(4,926)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	7,828
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	7,828
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	**1.6**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: During the September 2026 quarter, the Company had large payments associated with the pending USAMRIID dose escalation study, securing non-human primates associated with the Texas Biomed study BSL-4 facility costs, regulatory efforts in connection with clinical efforts in Africa and GMP manufacturing.The Company expects continued large R&D expenditure until NHP studies are complete.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: The Company has approximately $3.2million of options that are vested and in the money as at the date of this announcement. In addition, the Company is actively discussing and considering capital management and corporate plans. The Company is confident of funding the ongoing and future operations.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes, as per 8.6.2.

For personal use only

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

26 October 2026

Date: .....

The Board

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only